UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Epilepsy is a chronic brain condition where nerve cells in the brain send incorrect signals causing seizures Heres how it ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Three versions of synthetic psilocybin have received the US Food and Drug Administration’s “breakthrough therapy” designation — in 2018 for treatment-resistant depression, which is ...

Chronic pain and treatment-resistant depression both impact millions of people. Both can be debilitating and both can leave people feeling hopeless, impacting daily activities, relationships, and jobs ...

Non-steroidal anti-inflammatory drugs have been used in small ... THE BASICS Almost one-third of patients with major depression have treatment-resistant disease. This is defined as a lack of ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...